PURPOSE: Standard dose of external beam radiotherapy seems to be insufficient for satisfactory control of loco-regionally advanced @entity5 . Aim of our study is to evaluate the outcome as well as early and chronic @entity137 in @entity1 with loco-regionally advanced @entity5 , treated with dose escalated intensity modulated radiotherapy (IMRT) combined with @entity900 chemotherapy. MATERIAL AND METHODS: Thirty-nine @entity1 with @entity2622 FIGO stage @entity3847 - IVA were treated with curative intent between 2006 and 2010. The dose of 50.4  Gy was prescribed to the elective pelvic nodal volume. @entity5   <   4  cm in diameter (n   =   6; 15.4  %) received an external beam radiotherapy (EBRT) boost of 5.4  Gy, @entity5   >   4  cm in diameter (n   =   33; 84.6  %) received an EBRT boost of 9  Gy. @entity1 with positive lymph nodes detected with @entity419 -PET/CT (n   =   22; 56.4  %) received a boost to a total dose of 59.4 - 64.8  Gy. The para-aortic region was included in the radiation volume in 8 (20.5  %) @entity1 and in 5 (12.8  %) @entity1 the para-aortic macroscopic lymph nodes received an EBRT boost. IMRT was followed with a 3D planned high dose rate intrauterine brachytherapy given to 36 (92.3  %) @entity1 with a total dose ranging between 15-18  Gy in three fractions (single fraction: 4-6.5  Gy). @entity1 without contraindications (n   =   31/79.5  %) received concomitantly a @entity900 -based chemotherapy (40  mg/kg) weekly. @entity137 were graded according to the common terminology criteria for adverse events (CTCAE v 4.0). RESULTS: Mean overall survival for the entire cohort was 61.1  months (  3.5  months). Mean disease free survival was 47.2  months (  4.9  months) and loco-regional disease free survival was 55.2  months (  4.4  months). 65  % of @entity1 developed radiotherapy associated acute @entity137 grade 1, ca. 30  % developed @entity137 grade 2 and just two (5.2  %) @entity1 developed grade 3 @entity137 , one acute @entity294 and one @entity2335 . 16  % of @entity1 had chronic @entity137 grade 1, 9  % grade 2 and one @entity1 (2.6  %) @entity137 grade 3 in the form of vaginal dryness. CONCLUSION: Dose escalated IMRT appears to have a satisfactory outcome with regards to mean overall survival, disease free and loco-regional disease free survival, whereas the treatment-related @entity137 remain reasonably low.

Dose escalated intensity modulated radiotherapy in the treatment of XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities', 'Toxicities'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['(18)FDG'] @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumors', 'cervical cancer', 'Primary tumors'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity2622 :: ('MESH:D002583', 'Disease') :: ['cervical carcinoma'] @entity3847 :: ('23542', 'Gene') :: ['IB2'] @entity2335 :: ('MESH:D003556', 'Disease') :: ['acute cystitis']
@entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']
